.png)
Formula30A CBG
Gut Microbiome Study
Cannabigerol (CBG) is a non-psychoactive phytocannabinoid that engages gut-relevant targets, including CB2 receptors, TRP channels, and PPARs, with downstream effects on inflammation, epithelial barrier integrity, and gut microbiome composition and activity. In preclinical colitis models, CBG reduces inflammation and disease severity while shifting gut bacteria and metabolites toward a healthier profile, and in vitro it shows selective antimicrobial activity that can reshape bacterial communities.
However, limited clinical evidence exists for its effect on the human gut microbiome and digestive health markers. In our prior study investigating CBG consumption in healthy adults, daily full-spectrum CBG at a 50mg dose was well tolerated and produced no meaningful changes in symptoms or systemic inflammatory markers. The results corroborate previous preclinical and clinical findings indicating CBG has a strong safety profile and should be investigated in human trials for its therapeutic potential for patients with gastrointestinal (GI) disorders, such as irritable bowel syndrome (IBS), irritable bowel disease (IBD), Crohn’s disease, and ulcerative colitis.
Background and Context
Because gut immunity and digestion are closely linked to the microbiome, we measured stool microbiome diversity, secretory IgA, and fecal pancreatic elastase as exploratory indicators of mucosal immune and pancreatic function in adults with chronic gastrointestinal symptoms taking CBG.
Eight adult patients with chronic GI symptoms were enrolled. All participants underwent baseline comprehensive stool testing (Total GI™). Six patients repeated stool testing twice at 1-month intervals post-treatment; three patients repeated stool testing once at 1 month.
CBG supplementation (single 50mg capsule) was given twice daily for the treatment period. Changes in gut microbiome diversity, secretory IgA, and pancreatic elastase were assessed.
Test Article: 50mg CBG per dose consisting of solvent-free, hemp-derived full spectrum CBG extract and coconut (MCT) oil inside plant-based hydroxypropyl methylcellulose capsules manufactured by Formula30A, LLC. The formulation was third-party lab tested before, during, and after encapsulation to check for purity, consistency, and potential contaminants. Test articles are GMP Certified (Good Manufacturing Practice), non-GMO, pesticide free, solvent free, certified Kosher, and grown entirely in the USA.
Methodology
To evaluate the effects of CBG on gut microbiota diversity, digestive enzyme activity, and mucosal immune response in patients with known gastrointestinal (GI) disorders using a comprehensive stool analysis.
Objective
Anderson, B.D. et al. (2024) “High cannabigerol hemp extract moderates colitis and modulates the microbiome in an inflammatory bowel disease model,” The journal of pharmacology and experimental therapeutics, 390(3), pp. 331–341. Available at: https://doi.org/10.1124/jpet.124.002204.
Deiana, S. (2017) “Potential medical uses of cannabigerol: A brief overview,” in Handbook of Cannabis and Related Pathologies. Elsevier, pp. 958–967.
Good, L. and Baumgartner, J. (2023) “S648 proof of concept open label trial of CBD/CBG oral tincture in the management of symptoms in adult patients with irritable bowel syndrome,” The American journal of gastroenterology, 118(10S), pp. S474–S474. Available at: https://doi.org/10.14309/01.ajg.0000952232.28962.0b.
Li, S. et al. (2024) “Cannabigerol (CBG): A comprehensive review of its molecular mechanisms and therapeutic potential,” Molecules (Basel, Switzerland), 29(22). Available at: https://doi.org/10.3390/molecules29225471.
McLeod, C. et al. (2025) “Efficacy and safety of full spectrum cannabigerol (CBG) in healthy adults,” 28 May. Available at: https://posters.ifm.org/ifm/2025/2025-ifm/4157402/conor.mcleod.efficacy.and.safety.of.full.spectrum.cannabigerol.28cbg29.in.html.
Nachnani, R., Raup-Konsavage, W.M. and Vrana, K.E. (2021) “The pharmacological case for cannabigerol,” The journal of pharmacology and experimental therapeutics, 376(2), pp. 204–212. Available at: https://doi.org/10.1124/jpet.120.000340.
Russo, E.B. et al. (2021) “Survey of patients employing cannabigerol-predominant cannabis preparations: Perceived medical effects, adverse events, and withdrawal symptoms,” Cannabis and cannabinoid research [Preprint]. Available at: https://doi.org/10.1089/can.2021.0058.
Vitetta, L. et al. (2024) “Medicinal cannabis and the intestinal microbiome,” Pharmaceuticals (Basel, Switzerland), 17(12), p. 1702. Available at: https://doi.org/10.3390/ph17121702.
Zagožen, M., Čerenak, A. and Kreft, S. (2021) “Cannabigerol and cannabichromene in Cannabis sativa L,” Acta pharmaceutica (Zagreb, Croatia), 71(3), pp. 355–364. Available at: https://doi.org/10.2478/acph-2021-0021.